Everything you need to win FesariusTherapeutics — in one platform.
Who to reach, what to say, and why now on FesariusTherapeutics — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on FesariusTherapeutics — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
FesariusTherapeutics secures $20M in an oversubscribed Series A round, led by Jefferson Life Sciences, to advance its innovative DermiSphere technology.
PRIVATEJun 10, 2026•5 days ago
Amount Raised
$20 Million
Round Type
series a
New YorkManufacturingBiotechnologyHealth CareMedicalMedical Device
Investors
American Society Of Plastic SurgeonsEmpire State Development's Ny VenturesJohnson & JohnsonJefferson Life Sciences
Description
FesariusTherapeutics has successfully closed a $20 million Series A financing round. The round was led by Jefferson Life Sciences, alongside investors like Johnson & Johnson Innovation and NY Ventures. This funding will help accelerate the company's commercial infrastructure and support clinical trials for its flagship product, DermiSphere™. The investment marks a significant milestone for Fesarius as it builds commercial momentum in U.S
Company Information
Company
FesariusTherapeutics
Location
New York, New York, United States
About
FesariusTherapeutics is a commercial-stage medical technology company reimagining dermal repair. Its flagship product, DermiSphere™, is the first hydrogel Dermal Regeneration Template on the U.S. market, cleared by the FDA for managing various wound types. The company aims to transform wound care through innovative solutions that improve patient outcomes. With a focus on advancing its technologies, Fesarius is poised for significant growth in the medical device sector.
New YorkManufacturingBiotechnologyHealth CareMedicalMedical Device